Search

Your search keyword '"Collins, Colin C."' showing total 467 results
Start Over Author "Collins, Colin C."
467 results on '"Collins, Colin C."'

1. Establishment and validation of preclinical models of SMARCA4-inactivated and ARID1A/ARID1B co-inactivated dedifferentiated endometrial carcinoma

Author

Wong, Nelson K.Y., Llaurado Fernandez, Marta, Kommoss, Felix K.F., Praveen Kumar, Pooja, Kim, Hannah, Liu, Jiahui, Zhang, Guihua, Coatham, Mackenzie, Lin, Yen-Yi, Haegert, Anne M., Volik, Stanislav, Le Bihan, Stephane, Collins, Colin C., Fu, Yangxin, Postovit, Lynne M., von Deimling, Andreas, Wu, Rebecca, Xue, Hui, Wang, Yuzhuo, Köbel, Martin, Carey, Mark S., and Lee, Cheng-Han

Published
2023
Full Text
View/download PDF

2. The Proteogenomic Landscape of Curable Prostate Cancer

Author

Sinha, Ankit, Huang, Vincent, Livingstone, Julie, Wang, Jenny, Fox, Natalie S, Kurganovs, Natalie, Ignatchenko, Vladimir, Fritsch, Katharina, Donmez, Nilgun, Heisler, Lawrence E, Shiah, Yu-Jia, Yao, Cindy Q, Alfaro, Javier A, Volik, Stas, Lapuk, Anna, Fraser, Michael, Kron, Ken, Murison, Alex, Lupien, Mathieu, Sahinalp, Cenk, Collins, Colin C, Tetu, Bernard, Masoomian, Mehdi, Berman, David M, van der Kwast, Theodorus, Bristow, Robert G, Kislinger, Thomas, and Boutros, Paul C

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Bioinformatics and Computational Biology, Genetics, Oncology and Carcinogenesis, Aging, Biotechnology, Prostate Cancer, Cancer, Urologic Diseases, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Adult, Aged, Aged, 80 and over, Biomarkers, Tumor, Cell Line, Tumor, Epigenomics, Gene Expression Profiling, Humans, Male, Middle Aged, Prognosis, Prostatic Neoplasms, Proteogenomics, Proto-Oncogene Proteins c-ets, Translocation, Genetic, Whole Genome Sequencing, biomarker, epigenome, genome, multi-omic features, prostate cancer, proteome, transcriptome, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

DNA sequencing has identified recurrent mutations that drive the aggressiveness of prostate cancers. Surprisingly, the influence of genomic, epigenomic, and transcriptomic dysregulation on the tumor proteome remains poorly understood. We profiled the genomes, epigenomes, transcriptomes, and proteomes of 76 localized, intermediate-risk prostate cancers. We discovered that the genomic subtypes of prostate cancer converge on five proteomic subtypes, with distinct clinical trajectories. ETS fusions, the most common alteration in prostate tumors, affect different genes and pathways in the proteome and transcriptome. Globally, mRNA abundance changes explain only ∼10% of protein abundance variability. As a result, prognostic biomarkers combining genomic or epigenomic features with proteomic ones significantly outperform biomarkers comprised of a single data type.

Published
2019

4. ShatterProof: operational detection and quantification of chromothripsis

Author

Govind, Shaylan K, Zia, Amin, Hennings-Yeomans, Pablo H, Watson, John D, Fraser, Michael, Anghel, Catalina, Wyatt, Alexander W, van der Kwast, Theodorus, Collins, Colin C, McPherson, John D, Bristow, Robert G, and Boutros, Paul C

Subjects
Biological Sciences, Bioinformatics and Computational Biology, Genetics, Human Genome, Cancer, Biotechnology, Rare Diseases, Algorithms, Chromosome Aberrations, DNA Copy Number Variations, Gene Rearrangement, Genomics, High-Throughput Nucleotide Sequencing, Humans, Male, Neoplasms, Sequence Analysis, DNA, Software, Chromothripsis, Complex genomic rearrangement, Next generation sequencing, High throughput sequencing, Perl, Bioinformatics, Mathematical Sciences, Information and Computing Sciences, Biological sciences, Information and computing sciences, Mathematical sciences
Abstract

BackgroundChromothripsis, a newly discovered type of complex genomic rearrangement, has been implicated in the evolution of several types of cancers. To date, it has been described in bone cancer, SHH-medulloblastoma and acute myeloid leukemia, amongst others, however there are still no formal or automated methods for detecting or annotating it in high throughput sequencing data. As such, findings of chromothripsis are difficult to compare and many cases likely escape detection altogether.ResultsWe introduce ShatterProof, a software tool for detecting and quantifying chromothriptic events. ShatterProof takes structural variation calls (translocations, copy-number variations, short insertions and loss of heterozygosity) produced by any algorithm and using an operational definition of chromothripsis performs robust statistical tests to accurately predict the presence and location of chromothriptic events. Validation of our tool was conducted using clinical data sets including matched normal, prostate cancer samples in addition to the colorectal cancer and SCLC data sets used in the original description of chromothripsis.ConclusionsShatterProof is computationally efficient, having low memory requirements and near linear computation time. This allows it to become a standard component of sequencing analysis pipelines, enabling researchers to routinely and accurately assess samples for chromothripsis. Source code and documentation can be found at http://search.cpan.org/~sgovind/Shatterproof.

Published
2014

5. Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient‐derived, advanced prostate cancer tissue xenograft model

Author

Qu, Sifeng, Wang, Kendric, Xue, Hui, Wang, Yuwei, Wu, Rebecca, Liu, Chengfei, Gao, Allen C, Gout, Peter W, Collins, Colin C, and Wang, Yuzhuo

Subjects
Aging, Prostate Cancer, Cancer, Biotechnology, Urologic Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Animals, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Clinical Trials, Phase I as Topic, Docetaxel, Gene Expression Regulation, Neoplastic, Humans, Male, Mice, Mice, Inbred NOD, Neoplasms, Experimental, Prostatic Neoplasms, Taxoids, Xenograft Model Antitumor Assays, Aneustat, OMN54, Advanced prostate cancer, Microarray, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

The current first-line treatment for advanced metastatic prostate cancer, i.e. docetaxel-based therapy, is only marginally effective. The aim of the present study was to determine whether such therapy can be improved by combining docetaxel with Aneustat (OMN54), a multivalent botanical drug candidate shown to have anti-prostate cancer activity in preliminary in vitro experiments, which is currently undergoing a Phase-I Clinical Trial. Human metastatic, androgen-independent C4-2 prostate cancer cells and NOD-SCID mice bearing PTEN-deficient, metastatic and PSA-secreting, patient-derived subrenal capsule LTL-313H prostate cancer tissue xenografts were treated with docetaxel and Aneustat, alone and in combination. In vitro, Aneustat markedly inhibited C4-2 cell replication in a dose-dependent manner. When Aneustat was combined with docetaxel, the growth inhibitions of the drugs were essentially additive. In vivo, however, the combination of docetaxel and Aneustat enhanced anti-tumor activity synergistically and very markedly, without inducing major host toxicity. Complete growth inhibition and shrinkage of the xenografts could be obtained with the combined drugs as distinct from the drugs on their own. Analysis of the gene expression of the xenografts using microarray indicated that docetaxel + Aneustat led to expanded anticancer activity, in particular to targeting of cancer hallmarks that were not affected by the single drugs. Our findings, obtained with a highly clinically relevant prostate cancer model, suggest, for the first time, that docetaxel-based therapy of advanced human prostate cancer may be improved by combining docetaxel with Aneustat.

Published
2014

6. Immuno-oncology of Dormant Tumours

Author

Nabavi, Noushin, Roberts, Morgan E., Crea, Francesco, Collins, Colin C., Wang, Yuzhuo, Bishop, Jennifer L., Teicher, Beverly A., Series editor, Wang, Yuzhuo, editor, and Crea, Francesco, editor

Published
2017
Full Text
View/download PDF

8. The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E, Adler, Adam S, Kouros-Mehr, Hosein, Huang, Guiqing, Chou, Jonathan, Krig, Sheryl R, Griffith, Obi L, Korkola, James E, Qu, Kun, Lawson, Devon A, Xue, Qing, Sternlicht, Mark D, Dijkgraaf, Gerrit JP, Yaswen, Paul, Rugo, Hope S, Sweeney, Colleen A, Collins, Colin C, Gray, Joe W, Chang, Howard Y, and Werb, Zena

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Women's Health, Stem Cell Research, Precision Medicine, Cancer, Breast Cancer, Genetics, Stem Cell Research - Nonembryonic - Human, Aetiology, 4.1 Discovery and preclinical testing of markers and technologies, Detection, screening and diagnosis, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Animals, Antibiotics, Antineoplastic, Biomarkers, Tumor, Blotting, Western, Breast Neoplasms, Cell Line, Tumor, Cell Proliferation, Disease Progression, Doxorubicin, Drug Resistance, Neoplasm, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, MCF-7 Cells, Mice, NIH 3T3 Cells, Neoplastic Stem Cells, Oligonucleotide Array Sequence Analysis, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Ribonucleosides, Survival Analysis, Trans-Activators, Xenograft Model Antitumor Assays, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

UnlabelledThe transcription factor ZNF217 is a candidate oncogene in the amplicon on chromosome 20q13 that occurs in 20% to 30% of primary human breast cancers and that correlates with poor prognosis. We show that Znf217 overexpression drives aberrant differentiation and signaling events, promotes increased self-renewal capacity, mesenchymal marker expression, motility, and metastasis, and represses an adult tissue stem cell gene signature downregulated in cancers. By in silico screening, we identified candidate therapeutics that at low concentrations inhibit growth of cancer cells expressing high ZNF217. We show that the nucleoside analogue triciribine inhibits ZNF217-induced tumor growth and chemotherapy resistance and inhibits signaling events [e.g., phospho-AKT, phospho-mitogen-activated protein kinase (MAPK)] in vivo. Our data suggest that ZNF217 is a biomarker of poor prognosis and a therapeutic target in patients with breast cancer and that triciribine may be part of a personalized treatment strategy in patients overexpressing ZNF217. Because ZNF217 is amplified in numerous cancers, these results have implications for other cancers.SignificanceThis study finds that ZNF217 is a poor prognostic indicator and therapeutic target in patients with breast cancer and may be a strong biomarker of triciribine treatment efficacy in patients. Because previous clinical trials for triciribine did not include biomarkers of treatment efficacy, this study provides a rationale for revisiting triciribine in the clinical setting as a therapy for patients with breast cancer who overexpress ZNF217.

Published
2012

9. Figure S1 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer

Author

Kawai, Yoshihisa, primary, Imada, Kenjiro, primary, Akamatsu, Shusuke, primary, Zhang, Fan, primary, Seiler, Roland, primary, Hayashi, Tetsutaro, primary, Leong, Jeffrey, primary, Beraldi, Eliana, primary, Saxena, Neetu, primary, Kretschmer, Alexander, primary, Oo, Htoo Zarni, primary, Contreras-Sanz, Alberto, primary, Matsuyama, Hideyasu, primary, Lin, Dong, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Wyatt, Alexander W., primary, Black, Peter C., primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Table 3 from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

Author

Beltran, Himisha, primary, Rickman, David S., primary, Park, Kyung, primary, Chae, Sung Suk, primary, Sboner, Andrea, primary, MacDonald, Theresa Y., primary, Wang, Yuwei, primary, Sheikh, Karen L., primary, Terry, Stéphane, primary, Tagawa, Scott T., primary, Dhir, Rajiv, primary, Nelson, Joel B., primary, de la Taille, Alexandre, primary, Allory, Yves, primary, Gerstein, Mark B., primary, Perner, Sven, primary, Pienta, Kenneth J., primary, Chinnaiyan, Arul M., primary, Wang, Yuzhuo, primary, Collins, Colin C., primary, Gleave, Martin E., primary, Demichelis, Francesca, primary, Nanus, David M., primary, and Rubin, Mark A., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Information from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer

Author

Kawai, Yoshihisa, primary, Imada, Kenjiro, primary, Akamatsu, Shusuke, primary, Zhang, Fan, primary, Seiler, Roland, primary, Hayashi, Tetsutaro, primary, Leong, Jeffrey, primary, Beraldi, Eliana, primary, Saxena, Neetu, primary, Kretschmer, Alexander, primary, Oo, Htoo Zarni, primary, Contreras-Sanz, Alberto, primary, Matsuyama, Hideyasu, primary, Lin, Dong, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Wyatt, Alexander W., primary, Black, Peter C., primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

12. Data from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

13. Data from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

Author

Bishop, Jennifer L., primary, Thaper, Daksh, primary, Vahid, Sepideh, primary, Davies, Alastair, primary, Ketola, Kirsi, primary, Kuruma, Hidetoshi, primary, Jama, Randy, primary, Nip, Ka Mun, primary, Angeles, Arkhjamil, primary, Johnson, Fraser, primary, Wyatt, Alexander W., primary, Fazli, Ladan, primary, Gleave, Martin E., primary, Lin, Dong, primary, Rubin, Mark A., primary, Collins, Colin C., primary, Wang, Yuzhuo, primary, Beltran, Himisha, primary, and Zoubeidi, Amina, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table S2 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

Author

Bishop, Jennifer L., primary, Thaper, Daksh, primary, Vahid, Sepideh, primary, Davies, Alastair, primary, Ketola, Kirsi, primary, Kuruma, Hidetoshi, primary, Jama, Randy, primary, Nip, Ka Mun, primary, Angeles, Arkhjamil, primary, Johnson, Fraser, primary, Wyatt, Alexander W., primary, Fazli, Ladan, primary, Gleave, Martin E., primary, Lin, Dong, primary, Rubin, Mark A., primary, Collins, Colin C., primary, Wang, Yuzhuo, primary, Beltran, Himisha, primary, and Zoubeidi, Amina, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Table S1 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer

Author

Kawai, Yoshihisa, primary, Imada, Kenjiro, primary, Akamatsu, Shusuke, primary, Zhang, Fan, primary, Seiler, Roland, primary, Hayashi, Tetsutaro, primary, Leong, Jeffrey, primary, Beraldi, Eliana, primary, Saxena, Neetu, primary, Kretschmer, Alexander, primary, Oo, Htoo Zarni, primary, Contreras-Sanz, Alberto, primary, Matsuyama, Hideyasu, primary, Lin, Dong, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Wyatt, Alexander W., primary, Black, Peter C., primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target

Author

Collins, Colin C., primary, Volik, Stanislav V., primary, Lapuk, Anna V., primary, Wang, Yuwei, primary, Gout, Peter W., primary, Wu, Chunxiao, primary, Xue, Hui, primary, Cheng, Hongwei, primary, Haegert, Anne, primary, Bell, Robert H., primary, Brahmbhatt, Sonal, primary, Anderson, Shawn, primary, Fazli, Ladan, primary, Hurtado-Coll, Antonio, primary, Rubin, Mark A., primary, Demichelis, Francesca, primary, Beltran, Himisha, primary, Hirst, Martin, primary, Marra, Marco, primary, Maher, Christopher A., primary, Chinnaiyan, Arul M., primary, Gleave, Martin, primary, Bertino, Joseph R., primary, Lubin, Martin, primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 3 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

18. Data from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

Author

Beltran, Himisha, primary, Rickman, David S., primary, Park, Kyung, primary, Chae, Sung Suk, primary, Sboner, Andrea, primary, MacDonald, Theresa Y., primary, Wang, Yuwei, primary, Sheikh, Karen L., primary, Terry, Stéphane, primary, Tagawa, Scott T., primary, Dhir, Rajiv, primary, Nelson, Joel B., primary, de la Taille, Alexandre, primary, Allory, Yves, primary, Gerstein, Mark B., primary, Perner, Sven, primary, Pienta, Kenneth J., primary, Chinnaiyan, Arul M., primary, Wang, Yuzhuo, primary, Collins, Colin C., primary, Gleave, Martin E., primary, Demichelis, Francesca, primary, Nanus, David M., primary, and Rubin, Mark A., primary

Published
2023
Full Text
View/download PDF

19. Data from Next Generation Sequencing of Prostate Cancer from a Patient Identifies a Deficiency of Methylthioadenosine Phosphorylase, an Exploitable Tumor Target

Author

Collins, Colin C., primary, Volik, Stanislav V., primary, Lapuk, Anna V., primary, Wang, Yuwei, primary, Gout, Peter W., primary, Wu, Chunxiao, primary, Xue, Hui, primary, Cheng, Hongwei, primary, Haegert, Anne, primary, Bell, Robert H., primary, Brahmbhatt, Sonal, primary, Anderson, Shawn, primary, Fazli, Ladan, primary, Hurtado-Coll, Antonio, primary, Rubin, Mark A., primary, Demichelis, Francesca, primary, Beltran, Himisha, primary, Hirst, Martin, primary, Marra, Marco, primary, Maher, Christopher A., primary, Chinnaiyan, Arul M., primary, Gleave, Martin, primary, Bertino, Joseph R., primary, Lubin, Martin, primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Figure S1 - S8 from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

Author

Bishop, Jennifer L., primary, Thaper, Daksh, primary, Vahid, Sepideh, primary, Davies, Alastair, primary, Ketola, Kirsi, primary, Kuruma, Hidetoshi, primary, Jama, Randy, primary, Nip, Ka Mun, primary, Angeles, Arkhjamil, primary, Johnson, Fraser, primary, Wyatt, Alexander W., primary, Fazli, Ladan, primary, Gleave, Martin E., primary, Lin, Dong, primary, Rubin, Mark A., primary, Collins, Colin C., primary, Wang, Yuzhuo, primary, Beltran, Himisha, primary, and Zoubeidi, Amina, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 4 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figures 1-15, Supplementary Tables 1-2, Supplementary Methods from Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets

Author

Beltran, Himisha, primary, Rickman, David S., primary, Park, Kyung, primary, Chae, Sung Suk, primary, Sboner, Andrea, primary, MacDonald, Theresa Y., primary, Wang, Yuwei, primary, Sheikh, Karen L., primary, Terry, Stéphane, primary, Tagawa, Scott T., primary, Dhir, Rajiv, primary, Nelson, Joel B., primary, de la Taille, Alexandre, primary, Allory, Yves, primary, Gerstein, Mark B., primary, Perner, Sven, primary, Pienta, Kenneth J., primary, Chinnaiyan, Arul M., primary, Wang, Yuzhuo, primary, Collins, Colin C., primary, Gleave, Martin E., primary, Demichelis, Francesca, primary, Nanus, David M., primary, and Rubin, Mark A., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Table 2 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

24. SupplementaryTable S2 from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer

Author

Kawai, Yoshihisa, primary, Imada, Kenjiro, primary, Akamatsu, Shusuke, primary, Zhang, Fan, primary, Seiler, Roland, primary, Hayashi, Tetsutaro, primary, Leong, Jeffrey, primary, Beraldi, Eliana, primary, Saxena, Neetu, primary, Kretschmer, Alexander, primary, Oo, Htoo Zarni, primary, Contreras-Sanz, Alberto, primary, Matsuyama, Hideyasu, primary, Lin, Dong, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Wyatt, Alexander W., primary, Black, Peter C., primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

25. Data from Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer

Author

Kawai, Yoshihisa, primary, Imada, Kenjiro, primary, Akamatsu, Shusuke, primary, Zhang, Fan, primary, Seiler, Roland, primary, Hayashi, Tetsutaro, primary, Leong, Jeffrey, primary, Beraldi, Eliana, primary, Saxena, Neetu, primary, Kretschmer, Alexander, primary, Oo, Htoo Zarni, primary, Contreras-Sanz, Alberto, primary, Matsuyama, Hideyasu, primary, Lin, Dong, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Wyatt, Alexander W., primary, Black, Peter C., primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Table 1 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Materials and Methods from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Methods, Figures 1-4, Movie Legend, Table Legends 1-5 from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Movie from The Transcription Factor ZNF217 Is a Prognostic Biomarker and Therapeutic Target during Breast Cancer Progression

Author

Littlepage, Laurie E., primary, Adler, Adam S., primary, Kouros-Mehr, Hosein, primary, Huang, Guiqing, primary, Chou, Jonathan, primary, Krig, Sheryl R., primary, Griffith, Obi L., primary, Korkola, James E., primary, Qu, Kun, primary, Lawson, Devon A., primary, Xue, Qing, primary, Sternlicht, Mark D., primary, Dijkgraaf, Gerrit J.P., primary, Yaswen, Paul, primary, Rugo, Hope S., primary, Sweeney, Colleen A., primary, Collins, Colin C., primary, Gray, Joe W., primary, Chang, Howard Y., primary, and Werb, Zena, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Methods, Figure Legends from The Master Neural Transcription Factor BRN2 Is an Androgen Receptor–Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer

Author

Bishop, Jennifer L., primary, Thaper, Daksh, primary, Vahid, Sepideh, primary, Davies, Alastair, primary, Ketola, Kirsi, primary, Kuruma, Hidetoshi, primary, Jama, Randy, primary, Nip, Ka Mun, primary, Angeles, Arkhjamil, primary, Johnson, Fraser, primary, Wyatt, Alexander W., primary, Fazli, Ladan, primary, Gleave, Martin E., primary, Lin, Dong, primary, Rubin, Mark A., primary, Collins, Colin C., primary, Wang, Yuzhuo, primary, Beltran, Himisha, primary, and Zoubeidi, Amina, primary

Published
2023
Full Text
View/download PDF

32. Clonality Inference from Single Tumor Samples Using Low Coverage Sequence Data

Author

Donmez, Nilgun, Malikic, Salem, Wyatt, Alexander W., Gleave, Martin E., Collins, Colin C., Sahinalp, S. Cenk, Hutchison, David, Series editor, Kanade, Takeo, Series editor, Josef, Kittler, Series editor, Kleinberg, Jon M., Series editor, Mattern, Friedemann, Series editor, Mitchell, John C., Series editor, Naor, Moni, Series editor, Pandu Rangan, C., Series editor, Steffen, Bernhard, Series editor, Terzopoulos, Demetri, Series editor, Tygar, Doug, Series editor, Weikum, Gerhard, Series editor, and Singh, Mona, editor

Published
2016
Full Text
View/download PDF

34. Supplementary Table 5 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Author

Azad, Arun A., primary, Volik, Stanislav V., primary, Wyatt, Alexander W., primary, Haegert, Anne, primary, Le Bihan, Stephane, primary, Bell, Robert H., primary, Anderson, Shawn A., primary, McConeghy, Brian, primary, Shukin, Robert, primary, Bazov, Jenny, primary, Youngren, Jack, primary, Paris, Pamela, primary, Thomas, George, primary, Small, Eric J., primary, Wang, Yuzhuo, primary, Gleave, Martin E., primary, Collins, Colin C., primary, and Chi, Kim N., primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figure Legends and Mathods from Generation 2.5 Antisense Oligonucleotides Targeting the Androgen Receptor and Its Splice Variants Suppress Enzalutamide-Resistant Prostate Cancer Cell Growth

Author

Yamamoto, Yoshiaki, primary, Loriot, Yohann, primary, Beraldi, Eliana, primary, Zhang, Fan, primary, Wyatt, Alexander W., primary, Nakouzi, Nader Al, primary, Mo, Fan, primary, Zhou, Tianyuan, primary, Kim, Youngsoo, primary, Monia, Brett P., primary, MacLeod, A. Robert, primary, Fazli, Ladan, primary, Wang, Yuzhuo, primary, Collins, Colin C., primary, Zoubeidi, Amina, primary, and Gleave, Martin, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table S1 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Author

Luk, Iris Sze Ue, primary, Shrestha, Raunak, primary, Xue, Hui, primary, Wang, Yuwei, primary, Zhang, Fang, primary, Lin, Dong, primary, Haegert, Anne, primary, Wu, Rebecca, primary, Dong, Xin, primary, Collins, Colin C., primary, Zoubeidi, Amina, primary, Gleave, Martin E., primary, Gout, Peter W., primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

37. Figure S1 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer

Author

Flores-Morales, Amilcar, primary, Bergmann, Tobias B., primary, Lavallee, Charlotte, primary, Batth, Tanveer S., primary, Lin, Dong, primary, Lerdrup, Mads, primary, Friis, Stine, primary, Bartels, Anette, primary, Kristensen, Gitte, primary, Krzyzanowska, Agnieszka, primary, Xue, Hui, primary, Fazli, Ladan, primary, Hansen, Klaus H., primary, Røder, Martin A., primary, Brasso, Klaus, primary, Moreira, José M., primary, Bjartell, Anders, primary, Wang, Yuzhuo, primary, Olsen, Jesper V., primary, Collins, Colin C., primary, and Iglesias-Gato, Diego, primary

Published
2023
Full Text
View/download PDF

38. Table S6 from Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer

Author

Flores-Morales, Amilcar, primary, Bergmann, Tobias B., primary, Lavallee, Charlotte, primary, Batth, Tanveer S., primary, Lin, Dong, primary, Lerdrup, Mads, primary, Friis, Stine, primary, Bartels, Anette, primary, Kristensen, Gitte, primary, Krzyzanowska, Agnieszka, primary, Xue, Hui, primary, Fazli, Ladan, primary, Hansen, Klaus H., primary, Røder, Martin A., primary, Brasso, Klaus, primary, Moreira, José M., primary, Bjartell, Anders, primary, Wang, Yuzhuo, primary, Olsen, Jesper V., primary, Collins, Colin C., primary, and Iglesias-Gato, Diego, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Methods from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

Author

Vandekerkhove, Gillian, primary, Todenhöfer, Tilman, primary, Annala, Matti, primary, Struss, Werner J., primary, Wong, Amanda, primary, Beja, Kevin, primary, Ritch, Elie, primary, Brahmbhatt, Sonal, primary, Volik, Stanislav V., primary, Hennenlotter, Jörg, primary, Nykter, Matti, primary, Chi, Kim N., primary, North, Scott, primary, Stenzl, Arnulf, primary, Collins, Colin C., primary, Eigl, Bernhard J., primary, Black, Peter C., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

40. Supplementary figure S2 from BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer

Author

Luk, Iris Sze Ue, primary, Shrestha, Raunak, primary, Xue, Hui, primary, Wang, Yuwei, primary, Zhang, Fang, primary, Lin, Dong, primary, Haegert, Anne, primary, Wu, Rebecca, primary, Dong, Xin, primary, Collins, Colin C., primary, Zoubeidi, Amina, primary, Gleave, Martin E., primary, Gout, Peter W., primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Author

Azad, Arun A., primary, Volik, Stanislav V., primary, Wyatt, Alexander W., primary, Haegert, Anne, primary, Le Bihan, Stephane, primary, Bell, Robert H., primary, Anderson, Shawn A., primary, McConeghy, Brian, primary, Shukin, Robert, primary, Bazov, Jenny, primary, Youngren, Jack, primary, Paris, Pamela, primary, Thomas, George, primary, Small, Eric J., primary, Wang, Yuzhuo, primary, Gleave, Martin E., primary, Collins, Colin C., primary, and Chi, Kim N., primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table S1 from Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

Author

Kalina, Jennifer L., primary, Neilson, David S., primary, Lin, Yen-Yi, primary, Hamilton, Phineas T., primary, Comber, Alexandra P., primary, Loy, Emma M.H., primary, Sahinalp, S. Cenk, primary, Collins, Colin C., primary, Hach, Faraz, primary, and Lum, Julian J., primary

Published
2023
Full Text
View/download PDF

43. Supplementary Data from Multiomics Characterization of Low-Grade Serous Ovarian Carcinoma Identifies Potential Biomarkers of MEK Inhibitor Sensitivity and Therapeutic Vulnerability

Author

Shrestha, Raunak, primary, Llaurado Fernandez, Marta, primary, Dawson, Amy, primary, Hoenisch, Joshua, primary, Volik, Stanislav, primary, Lin, Yen-Yi, primary, Anderson, Shawn, primary, Kim, Hannah, primary, Haegert, Anne M., primary, Colborne, Shane, primary, Wong, Nelson K.Y., primary, McConeghy, Brian, primary, Bell, Robert H., primary, Brahmbhatt, Sonal, primary, Lee, Cheng-Han, primary, DiMattia, Gabriel E., primary, Le Bihan, Stephane, primary, Morin, Gregg B., primary, Collins, Colin C., primary, and Carey, Mark S., primary

Published
2023
Full Text
View/download PDF

44. Supplementary Table 2 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Author

Azad, Arun A., primary, Volik, Stanislav V., primary, Wyatt, Alexander W., primary, Haegert, Anne, primary, Le Bihan, Stephane, primary, Bell, Robert H., primary, Anderson, Shawn A., primary, McConeghy, Brian, primary, Shukin, Robert, primary, Bazov, Jenny, primary, Youngren, Jack, primary, Paris, Pamela, primary, Thomas, George, primary, Small, Eric J., primary, Wang, Yuzhuo, primary, Gleave, Martin E., primary, Collins, Colin C., primary, and Chi, Kim N., primary

Published
2023
Full Text
View/download PDF

45. Table S1 to S5 from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

Author

Vandekerkhove, Gillian, primary, Todenhöfer, Tilman, primary, Annala, Matti, primary, Struss, Werner J., primary, Wong, Amanda, primary, Beja, Kevin, primary, Ritch, Elie, primary, Brahmbhatt, Sonal, primary, Volik, Stanislav V., primary, Hennenlotter, Jörg, primary, Nykter, Matti, primary, Chi, Kim N., primary, North, Scott, primary, Stenzl, Arnulf, primary, Collins, Colin C., primary, Eigl, Bernhard J., primary, Black, Peter C., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figures from Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer

Author

Vandekerkhove, Gillian, primary, Todenhöfer, Tilman, primary, Annala, Matti, primary, Struss, Werner J., primary, Wong, Amanda, primary, Beja, Kevin, primary, Ritch, Elie, primary, Brahmbhatt, Sonal, primary, Volik, Stanislav V., primary, Hennenlotter, Jörg, primary, Nykter, Matti, primary, Chi, Kim N., primary, North, Scott, primary, Stenzl, Arnulf, primary, Collins, Colin C., primary, Eigl, Bernhard J., primary, Black, Peter C., primary, and Wyatt, Alexander W., primary

Published
2023
Full Text
View/download PDF

47. Data from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

Author

Ci, Xinpei, primary, Hao, Jun, primary, Dong, Xin, primary, Choi, Stephen Y., primary, Xue, Hui, primary, Wu, Rebecca, primary, Qu, Sifeng, primary, Gout, Peter W., primary, Zhang, Fang, primary, Haegert, Anne M., primary, Fazli, Ladan, primary, Crea, Francesco, primary, Ong, Christopher J., primary, Zoubeidi, Amina, primary, He, Housheng H., primary, Gleave, Martin E., primary, Collins, Colin C., primary, Lin, Dong, primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Tables from Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy

Author

Beltran, Himisha, primary, Wyatt, Alexander W., primary, Chedgy, Edmund C., primary, Donoghue, Adam, primary, Annala, Matti, primary, Warner, Evan W., primary, Beja, Kevin, primary, Sigouros, Michael, primary, Mo, Fan, primary, Fazli, Ladan, primary, Collins, Colin C., primary, Eastham, James, primary, Morris, Michael, primary, Taplin, Mary-Ellen, primary, Sboner, Andrea, primary, Halabi, Susan, primary, and Gleave, Martin E., primary

Published
2023
Full Text
View/download PDF

49. Supplementary Information from Heterochromatin Protein 1α Mediates Development and Aggressiveness of Neuroendocrine Prostate Cancer

Author

Ci, Xinpei, primary, Hao, Jun, primary, Dong, Xin, primary, Choi, Stephen Y., primary, Xue, Hui, primary, Wu, Rebecca, primary, Qu, Sifeng, primary, Gout, Peter W., primary, Zhang, Fang, primary, Haegert, Anne M., primary, Fazli, Ladan, primary, Crea, Francesco, primary, Ong, Christopher J., primary, Zoubeidi, Amina, primary, He, Housheng H., primary, Gleave, Martin E., primary, Collins, Colin C., primary, Lin, Dong, primary, and Wang, Yuzhuo, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Table 1 from Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer

Author

Azad, Arun A., primary, Volik, Stanislav V., primary, Wyatt, Alexander W., primary, Haegert, Anne, primary, Le Bihan, Stephane, primary, Bell, Robert H., primary, Anderson, Shawn A., primary, McConeghy, Brian, primary, Shukin, Robert, primary, Bazov, Jenny, primary, Youngren, Jack, primary, Paris, Pamela, primary, Thomas, George, primary, Small, Eric J., primary, Wang, Yuzhuo, primary, Gleave, Martin E., primary, Collins, Colin C., primary, and Chi, Kim N., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results